Opinion

Video

Patient Selection for Port Delivery System

Author(s):

Aleksandra Rachitskaya, MD,Jordan Graff, MD, FACS

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their number of clinic visits while maintaining therapeutic effectiveness.

Video content above is prompted by the following:

  • Which patients are ideal candidates for this anti-VEGF delivery method?
  • Patients with frequent anti-VEGF treatment burden (4-8 weeks)

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
Related Content
(Image credit: AdobeStock/zinkevych) FDA nod for acoltremon: What its approval means for clinicians and patients
June 7th 2025

FDA nod for acoltremon: What its approval means for clinicians and patients

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/peshkova)
May 17th 2025

Q&A: Joaquin De Rojas, MD, on ASCRS 2025 Best Paper of Session for advancing AK with machine learning

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
May 10th 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

(Image credit: AdobeStock/Roman)
April 30th 2025

ASCRS 2025: Visual and patient-reported outcomes following bilateral Odyssey implantation

© 2025 MJH Life Sciences

All rights reserved.